Summary
The a2 Milk Company updated shareholders on the recovery of its China infant milk formula business and its FY27 outlook at its annual meeting on 18 November 2026. A shortage of China-label IMF products materially affected in-market availability in 4Q26, prompting many existing users to switch to other brands, with flow-on effects expected to weigh on FY27 IMF sales. The US-label IMF recall announced in May 2026 also indirectly affected 4Q26 English-label IMF shipments.
The company said it is focused on executing its China IMF recovery plan, with China-label product shipments estimated to have recovered to about 50 percent of pre-disruption levels, up from about 40 percent in August 2026. For FY27, a2MC expects revenue and EBITDA growth, driven by increased contributions from product innovation and new markets, continued momentum in other nutritional products and liquid milk, and improved a2 Pōkeno profitability. However, total IMF sales are expected to be broadly in line with FY26, with China-label and English-label products recovering progressively through FY27, supported by two recently launched China-label products and an upgraded a2 Platinum, and by resolution of the China import requirements currently affecting a2 Genesis.
The recovery will be supported by increased marketing investment, particularly in 1H27. Group revenue and EBITDA are therefore expected to be significantly weighted to 2H27. The transition of a2 Platinum to a2 Pōkeno is on track, with one-off transition costs now expected to be about NZ$15 million in FY27 and no transition costs expected in FY28.
The company also noted that the New Zealand dollar has depreciated since its last outlook, which at current exchange rates is expected to increase group revenue and expenses, with the related net benefit uplift offset by hedging losses. For FY27 (continuing operations basis) compared with FY26, the company expects mid single-digit percentage revenue growth, with 1H27 revenue slightly lower than 1H26; an underlying EBITDA margin of about 15 percent, with 1H27 significantly lower than 1H26; depreciation and amortisation of about NZ$20 million; cash conversion of about 70 to 80 percent; and capital expenditure of about NZ$70 million. Key risks identified include the extent and pace of the China IMF recovery, trading upside and downside, macroeconomic conditions, category dynamics and competitive intensity, product and supply-related risks, cross-border trade, exchange rate movements, interest rate changes, farmgate milk prices and other commodity prices, regulatory risk, import and export requirements, Middle East conflict, a2 Pōkeno transformation and transition risks, and geopolitical risk.
The announcement was authorised by the board and signed by Managing Director and Chief Executive Officer David Bortolussi.
Commentary
The a2 Milk Company has disclosed progress on the recovery of its China infant milk formula business and its FY27 outlook at its annual meeting, showing it is gradually recovering from supply chain disruption but that challenges remain significant. China-label product shipments have recovered to about 50 percent of pre-disruption levels, up from 40 percent in August, but this still means many consumers have switched to competitors, damaging brand loyalty. a2MC expects total FY27 IMF sales to be flat on FY26, with growth relying mainly on product innovation, other nutritional products and liquid milk, and improved a2 Pōkeno profitability.
For New Zealand small and medium business owners, this case highlights the dual pressures of Chinese market regulation and supply chain risk. China is the world’s largest IMF market, but competition is intense, with domestic brands such as Feihe and Yili dominant, and regulatory policies (such as the formula registration system) frequently adjusted, requiring imported brands to keep investing in compliance and marketing resources. a2MC’s recovery plan includes launching two new China-label products and an upgraded a2 Platinum, and increasing marketing investment, particularly in 1H27, which may pressure short-term margins (FY27 underlying EBITDA margin is expected at about 15 percent, with 1H27 significantly lower).
In addition, while a weaker New Zealand dollar may lift revenue, this is offset by hedging losses, and exchange rate volatility remains an important variable. From an industry perspective, a2MC’s difficulties reflect common challenges facing premium imported formula in the China market: a declining birth rate is shrinking the overall market, while under the consumption upgrade trend niche categories (such as A2 protein and organic) still have room for growth, but supply chain localisation and brand building are costly. New Zealand dairy exporters should watch changes in China’s import requirements (such as the import restrictions facing a2 Genesis) and consider diversifying market exposure to reduce reliance on a single market.
a2MC expects mid single-digit FY27 revenue growth but significantly weighted to the second half, indicating recovery will take time. For NZ SMEs reliant on the China market, it is advisable to closely track China’s formula registration and cross-border e-commerce policies, while assessing supply chain resilience to avoid over-concentration risk.
Keywords: a2 Milk, China infant milk formula, FY27 outlook, supply chain disruption, a2 Pōkeno, EBITDA margin, shipment recovery, a2 Platinum, New Zealand dollar depreciation, transition costs
Photo from Unsplash (placeholder)
Source: NZX
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.





